Publicaciones en colaboración con investigadores/as de University of Pittsburgh School of Medicine (42)

2024

  1. A plasma peptidomic signature reveals extracellular matrix remodeling and predicts prognosis in alcohol-associated hepatitis

    Hepatology Communications, Vol. 8, Núm. 8

  2. Acute kidney disease beyond day 7 after major surgery: a secondary analysis of the EPIS-AKI trial

    Intensive Care Medicine, Vol. 50, Núm. 2, pp. 247-257

  3. Application of Graph Models to the Identification of Transcriptomic Oncometabolic Pathways in Human Hepatocellular Carcinoma

    Biomolecules, Vol. 14, Núm. 6

  4. Event-free survival of maralixibat-treated patients with Alagille syndrome compared to a real-world cohort from GALA

    Hepatology (Baltimore, Md.), Vol. 79, Núm. 6, pp. 1279-1292

  5. The heterogeneous sensitivity of pediatric brain tumors to different oncolytic viruses is predicted by unique gene expression profiles

    Molecular Therapy Oncology, Vol. 32, Núm. 2

2023

  1. Author Correction: Defective HNF4alpha-dependent gene expression as a driver of hepatocellular failure in alcoholic hepatitis (Nature Communications, (2019), 10, 1, (3126), 10.1038/s41467-019-11004-3)

    Nature Communications

  2. Candidate diagnostic biomarkers for neurodevelopmental disorders in children and adolescents: a systematic review

    World Psychiatry, Vol. 22, Núm. 1, pp. 129-149

  3. Design and methodological considerations for biomarker discovery and validation in the Integrative Analysis of Lung Cancer Etiology and Risk (INTEGRAL) Program

    Annals of Epidemiology, Vol. 77, pp. 1-12

  4. Epidemiology of surgery associated acute kidney injury (EPIS-AKI): a prospective international observational multi-center clinical study

    Intensive Care Medicine, Vol. 49, Núm. 12, pp. 1441-1455

2022

  1. Genomic profiling for clinical decision making in lymphoid neoplasms

    Blood

  2. Integrated Transcriptomic and Proteomic Analysis Identifies Plasma Biomarkers of Hepatocellular Failure in Alcohol-Associated Hepatitis

    American Journal of Pathology, Vol. 192, Núm. 12, pp. 1658-1669

  3. Patient-reported outcomes in relapsed/refractory multiple myeloma treated with melflufen plus dexamethasone: analyses from the Phase II HORIZON study

    British Journal of Haematology, Vol. 196, Núm. 3, pp. 639-648

  4. The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee

    Blood, Vol. 140, Núm. 11, pp. 1229-1253

2021

  1. CRIg on liver macrophages clears pathobionts and protects against alcoholic liver disease

    Nature Communications, Vol. 12, Núm. 1

  2. Endothelial dysfunction markers predict short-term mortality in patients with severe alcoholic hepatitis

    Hepatology International, Vol. 15, Núm. 4, pp. 1006-1017

  3. Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)1

    Autophagy, Vol. 17, Núm. 1, pp. 1-382

  4. Melflufen and Dexamethasone in Heavily Pretreated Relapsed and Refractory Multiple Myeloma

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 39, Núm. 7, pp. 757-767

2020

  1. Consensus guidelines for the definition, detection and interpretation of immunogenic cell death

    Journal for ImmunoTherapy of Cancer, Vol. 8, Núm. 1

2019

  1. Defective HNF4alpha-dependent gene expression as a driver of hepatocellular failure in alcoholic hepatitis

    Nature Communications, Vol. 10, Núm. 1

  2. Deficient IL-6/Stat3 Signaling, High TLR7, and Type I Interferons in Early Human Alcoholic Liver Disease: A Triad for Liver Damage and Fibrosis

    Hepatology Communications, Vol. 3, Núm. 7, pp. 867-882